BFM
TGTX icon

Boothbay Fund Management’s TG Therapeutics TGTX Stock Holding History

Boothbay Fund Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-167,800
Closed -$4.17M – 2077
2023
Q2 		$4.17M Buy
+167,800
New +$4.33M 0.09% 276
2021
Q4 		– Sell
-9,900
Closed -$329K – 2223
2021
Q3 		$329K Sell
9,900
-1,400
-12% -$43.3K 0.01% 1284
2021
Q2 		$438K Buy
11,300
+11,187
+9,900% +$439K 0.01% 1073
2021
Q1 		$545K Hold
113
– – 0.02% 900
2020
Q4 		$588K Buy
+113
New +$3.82K 0.02% 684

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Boothbay Fund Management's TGTX Position: Q1 2026 in Review

Boothbay Fund Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 26,761 shares — an estimated $798K sold.

Boothbay Fund Management first reported a position in TGTX in Q3 2018 and held it in 13 quarters. The position peaked at $2.57M in Q4 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Boothbay Fund Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 26,761 TG Therapeutics shares in Q1 2026, an estimated $798K.
  • Boothbay Fund Management first reported a position in TG Therapeutics in Q3 2018 and held it in 13 quarters.
  • Boothbay Fund Management's TG Therapeutics position peaked at $2.57M in Q4 2024.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.